During early drug development and preclinical development, researchers use in vitro cultured lymphocytes to induce cytokine ...

T cells are a natural part of the immune system designed to fight infections and cancer, but in conditions like blood cancer, they may not be able to eliminate malignant cells, according to Dr.

Researchers at the University of California Davis Comprehensive Cancer Center have uncovered an evolutionary change that may ...

HR-positive/HER2-negative is the most common subtype of breast cancer in women. HR-positive/HER2-negative metastatic breast ...

DelveInsight’s Metastatic Prostate Cancer Pipeline report depicts a robust space with 80+ active players working to develop ...

Eight researchers specializing in adult oncology from Fred Hutch Cancer Center and the University of Washington have been ...

DelveInsight's Rheumatoid Arthritis Pipeline report depicts a robust space with 75+ active players working to develop 80+ ...

An expert highlights that the future of metastatic castration-resistant prostate cancer (mCRPC) treatment is advancing with novel drug classes such as radioligand therapies, proteolysis-targeting ...

A little-known molecule may be the key to treating aggressive cancer that often strikes young people, a study from ...

Tumor progression locus 2, a new potential prognostic factor and therapeutic target in activated B-cell-like diffuse large B-cell lymphoma Kota Yoshifuji Yotaro Motomura Toshikage Nagao ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

Aberrations in fibroblast growth factor receptors FGFR2/3 are major drivers of many cancers—including intrahepatic cholangiocarcinoma, endometrial ...